The market for weight-loss drugs is booming. Not only the pharmaceutical companies offering the medication are benefiting, but also their suppliers. Among them are the Swiss companies Bachem and Ypsomed.

Global equity markets are plunging. In this environment, products with defensive features are in favour.

After a period of weakness, Roche shares are making a comeback. This makes the pharmaceutical giant the most valuable Swiss company, pushing Nestlé into second place. 

US equity markets are dominated by a handful of technology companies. In the upcoming earnings season, they will once again be the centre of attention, as the expectations for Wall Street's stars are high. 

The outlook for gold miners seems bright given the high price of gold. But it is not just the precious metal that is expensive; the gold industry's production costs have also recently hit record highs. 

«When I was your age, television was called books.» – William Goldman

The need for entertainment is a constant, yet the forms in which it is consumed are changing and evolving. What does the entertainment landscape look like these days, and how do Netflix and Disney secure their share of our time?

The Swiss equity market has experienced a positive first half-year. This is reflected in the SMI, which has risen significantly since the beginning of the year. However, the performance of individual stocks varies considerably. 

Straumann shares are under pressure on stock markets. Although the first quarter has been solid, weaker growth in the medtech company's main markets seems to displease investors. 

Nike's collaboration with basketball star Michael Jordan is one of the most prominent sponsorship stories in the world of sport. Today, sports sponsorship is a popular marketing strategy for leading companies. However, measuring success is difficult and the commitment has its pitfalls.

For a few months, it has been possible to fill medical prescriptions in Germany via app. This has triggered a race for market share. So far, however, the two e-pharmacies DocMorris and Redcare Pharmacy have not been able to convince stock markets.